Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella sonnei O-SP-core conjugate vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Child Health and Human Development
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Shigella sonnei O-SP-core conjugate vaccine (O-SPC-rDT) is an investigational glycoconjugate vaccine developed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for the prevention of shigellosis. The vaccine consists of a fragment of the *Shigella sonnei* lipopolysaccharide (LPS), comprising the O-specific polysaccharide (O-SP) and the core region (O-SPC), which is covalently bound to a recombinant non-toxic diphtheria toxin mutant (rDT) carrier protein. The saccharide component is designed with a low molecular mass, averaging 3.5 repeat units, and is coupled via its reducing end to enhance immunogenicity compared to previous full-length O-SP conjugates. The vaccine's mechanism of action involves eliciting type-specific serum IgG antibodies against the O-SP domain, an essential virulence factor and protective antigen of *S. sonnei*. It is currently being evaluated in Phase 1 clinical trials to assess safety and immunogenicity in healthy adults, with the ultimate goal of providing protection to young children, the population most affected by shigellosis.
- Brand names
- Shigella sonnei O-SPC/rBRU
- Other names
- Shigella sonnei OSPC-rDT Conjugate VaccineS. sonnei O-SP-core conjugate vaccine
Beyond the preview
Go deeper on Shigella sonnei O-SP-core conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella sonnei O-SP-core conjugate vaccine.